DOAC与靶向抗癌药联用的出血与血栓结局:TacDOAC注册研究
大出血累积发生率4%,非大出血6%,BTK抑制剂使用者大出血发生率最高达10%;VTE与动脉血栓累积发生率分别为1.5%和1.0%。出血风险高于血栓风险。
要点
- 联用DOAC与靶向药时出血风险高于血栓风险,需重点监测出血。
- BTK抑制剂使用者大出血累积发生率最高,为10%。
- 6个月内VTE与动脉血栓累积发生率分别为1.5%和1.0%。
核心结论
- 同时使用DOAC与靶向抗癌药的患者中,出血发生率高于血栓形成,尤其是BTK抑制剂使用者。
研究设计与样本
- 患者因VTE或房颤使用DOAC并联用特定靶向抗癌药,自联用开始随访6个月。
主要发现
- 最常见恶性肿瘤为血液系统肿瘤57例(28.2%),其次乳腺癌50例(24.8%)和肺癌44例(21.8%)。
- 最常见抗癌治疗为EGFR和ALK抑制剂43例(21.3%),其次BTK抑制剂42例(20.8%)和palbociclib 42例(20.8%)。
- 随访期间发生9例大出血和12例非大出血,累积发生率分别为4%(95%CI 2-8%)和6%(95%CI 3-10%)。
- BTK抑制剂使用者大出血累积发生率最高,为10%。
- 发生3例VTE和2例动脉血栓,累积发生率分别为1.5%(95%CI 0.4-4.0%)和1.0%(95%CI 0.2-3.3%)。
临床怎么用
- 对联用DOAC与靶向抗癌药的患者,应重视出血监测,尤其是使用BTK抑制剂者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer patients are increasingly prescribed direct oral anticoagulants (DOACs) and targeted anticancer therapies, but limited data are available on the outcomes during concurrent use. OBJECTIVES: We conducted an international registry through the Scientific and Standardization Committee of the ISTH to evaluate the characteristics, bleeding, and thrombotic outcomes in patients receiving concurrent DOACs and targeted anticancer therapies. PATIENTS/METHODS: Patients receiving concurrent DOACs for venous thromboembolism (VTE) or atrial fibrillation and selected targeted anticancer therapies were followed for 6 months after the start of concurrent use. Data including patient and cancer characteristics, major bleeding, non-major bleeding events, and venous or arterial thromboses were collected. RESULTS: Two hundred and two patients were included from six institutions in the United States and Israel. The most common malignancies were hematologic (N = 57, 28.2%), followed by breast (N = 50, 24.8%) and lung (N = 44, 21.8%). The most common anticancer therapies were epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors (N = 43, 21.3%), followed by Bruton's tyrosine kinase (BTK) inhibitors (N = 42, 20.8%) and palbociclib (N = 42, 20.8%). During follow-up, there were 9 major bleeding and 12 non-major bleeding events, corresponding to cumulative incidences of 4% (95% confidence interval [CI]: 2-8%) and 6% (95% CI: 3-10%), respectively. The cumulative incidence of major bleeding events was highest in BTK inhibitor users (10%). There were 3 VTE and 2 arterial thromboses, corresponding to cumulative incidences of 1.5% (95% CI: 0.4-4.0%) and 1.0% (95% CI: 0.2-3.3%), respectively. CONCLUSIONS: In this cohort receiving concurrent DOACs and targeted anticancer therapies, the incidence of bleeding is higher compared to thrombosis, particularly with BTK inhibitors. Future larger prospective studies are needed.
引用
- Wang TF, Baumann Kreuziger L, Leader A, et al. Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost. 2021. PMID: 34327825. doi:10.1111/jth.15367
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。